HUP0202972A2 - Vazopresszin antagonista készítmény és eljárás az előállítására - Google Patents

Vazopresszin antagonista készítmény és eljárás az előállítására

Info

Publication number
HUP0202972A2
HUP0202972A2 HU0202972A HUP0202972A HUP0202972A2 HU P0202972 A2 HUP0202972 A2 HU P0202972A2 HU 0202972 A HU0202972 A HU 0202972A HU P0202972 A HUP0202972 A HU P0202972A HU P0202972 A2 HUP0202972 A2 HU P0202972A2
Authority
HU
Hungary
Prior art keywords
preparation
vasopressin antagonist
antagonist formulation
novel
formulation
Prior art date
Application number
HU0202972A
Other languages
English (en)
Inventor
Mahdi Bakir Fawzi
Richard William Saunders
Joseph Kyuwung Yoon
Original Assignee
American Cyanamid Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co. filed Critical American Cyanamid Co.
Publication of HUP0202972A2 publication Critical patent/HUP0202972A2/hu
Publication of HUP0202972A3 publication Critical patent/HUP0202972A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Abstract

A találmány tárgya új N-(4-(5H-pirrolo(2,1-c)(1,4]benzodiazepin-10(11H)-ilkarbonil)-3-klórfenil)-5-fluor-2-metil-benzamidot vagygyógyászatilag elfogadható sóját tartalmazó új gyógyászatikészítmények és eljárás a készítmények előállítására. A készítménykörülbelül 1-20% hatóanyagot, körülbelül 1-18 felületaktív komponenst,körülbelül 50-80% egy vagy több polietilén-glikolt, körülbelül 1-20%egy vagy több szacharóz zsírsav észtert és/vagy polivinil-pirrolidontés adott esetben egy vagy több gyógyászatilag elfogadhatókonzerválószert vagy antioxidánst tartalmaz. Ó
HU0202972A 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process for its preparation HUP0202972A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40577299A 1999-09-27 1999-09-27
PCT/US2000/026369 WO2001022945A1 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process

Publications (2)

Publication Number Publication Date
HUP0202972A2 true HUP0202972A2 (hu) 2002-12-28
HUP0202972A3 HUP0202972A3 (en) 2003-07-28

Family

ID=23605168

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202972A HUP0202972A3 (en) 1999-09-27 2000-09-26 Vasopressin antagonist formulation and process for its preparation

Country Status (18)

Country Link
EP (1) EP1216033A1 (hu)
JP (1) JP2003510269A (hu)
KR (1) KR20020039354A (hu)
CN (1) CN1391466A (hu)
AR (1) AR025780A1 (hu)
AU (1) AU7615000A (hu)
BR (1) BR0014351A (hu)
CA (1) CA2388474A1 (hu)
CZ (1) CZ20021083A3 (hu)
EA (1) EA200200414A1 (hu)
HK (1) HK1045109A1 (hu)
HU (1) HUP0202972A3 (hu)
IL (1) IL148541A0 (hu)
MX (1) MXPA02003189A (hu)
NO (1) NO20021475L (hu)
PL (1) PL354282A1 (hu)
WO (1) WO2001022945A1 (hu)
ZA (1) ZA200203312B (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
AU2003211267A1 (en) * 2002-02-27 2003-09-09 Shionogi And Co., Ltd. Solid preparations with improved absorbability of hardly water-soluble drug
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) * 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
EP1049459B1 (en) * 1998-01-20 2009-04-22 Applied Analytical Industries, Inc. Oral liquid compositions

Also Published As

Publication number Publication date
MXPA02003189A (es) 2002-09-30
KR20020039354A (ko) 2002-05-25
IL148541A0 (en) 2002-09-12
EP1216033A1 (en) 2002-06-26
CZ20021083A3 (cs) 2002-06-12
AR025780A1 (es) 2002-12-11
HUP0202972A3 (en) 2003-07-28
ZA200203312B (en) 2003-12-31
WO2001022945A1 (en) 2001-04-05
CA2388474A1 (en) 2001-04-05
CN1391466A (zh) 2003-01-15
EA200200414A1 (ru) 2002-12-26
NO20021475D0 (no) 2002-03-25
HK1045109A1 (zh) 2002-11-15
NO20021475L (no) 2002-04-16
BR0014351A (pt) 2002-06-11
PL354282A1 (en) 2003-12-29
AU7615000A (en) 2001-04-30
JP2003510269A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
GB9914486D0 (en) Medicaments
AU3753695A (en) Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists
WO2001042219A3 (en) Novel substituted phenanthridinones and methods of use thereof
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
EP2269608A3 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
AU1247195A (en) Cyclic amide derivatives as neurokinin a antagonists
AU2003239389A1 (en) Opioid receptor antagonists
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
NO973652D0 (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
GEP20074127B (en) Proline derivatives having affinity for the calcium channel alpha-2-delta subunit
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
ZA979647B (en) Heterocyclic compounds, compositions and uses.
HUP0202972A2 (hu) Vazopresszin antagonista készítmény és eljárás az előállítására
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
HUP0400889A3 (en) Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and pharmaceutical compositions containing the compound
HUP9702448A2 (hu) Indolkarbonsavat tartalmazó, parenterálisan adható gyógyászati készítmény
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
ZA979645B (en) Heterocyclic compounds, compositions and uses.
ZA979650B (en) Heterocyclic compounds, compositions and uses.
SE9901773D0 (sv) Förebyggande av karies i tänderna
HUP0301973A2 (hu) Opioid hatású vegyületet és (I) általános képletű vegyületet tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmények
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease